Subsequently, Mcl-1 was found to be an essential pro-survival molecule in multiple tumor types, warranting the recent advancements of Mcl-1 specific BH3-mimetics in clinical trials, including AMG-176 (Amgen) (Caenepeel et al., 2018), S64315 (Servier) (Szlavik et al., 2020), and AZD5991 (AstraZeneca) (Tron et al., 2018) [reviewed in detail elsewhere (Xiang et al., 2018; Kelly and Strasser, 2020)]. The gene discussed is MCL1; the disease is neoplasm.